WallStreetZenWallStreetZen

NASDAQ: PRLD
Prelude Therapeutics Inc Stock Ownership - Who owns Prelude Therapeutics?

OverviewForecastEarningsRevenueDividendOwnership

Insider buying vs selling

Have Prelude Therapeutics Inc insiders been buying or selling?
Buy
Sell
NameRoleDateSharesPriceValue
Jane HuangPresident CMO2024-10-043,349$2.00
$6.70kSell
Jane HuangPresident CMO2024-07-043,347$3.60
$12.05kSell
Jane HuangPresident CMO2024-04-043,347$4.74
$15.86kSell
Jane HuangPresident CMO2024-01-043,844$3.77
$14.49kSell

1 of 1

PRLD insiders have sold more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when PRLD insiders and whales buy or sell their stock.

PRLD Shareholders

What type of owners hold Prelude Therapeutics Inc stock?
Institutional
Insider
Retail
NameHoldSharesValueType
Orbimed Advisors LLC19.83%10,909,256$21.82MInstitution
Baker Bros Advisors LP18.40%10,123,824$20.25MInstitution
Orbimed Advisors LLC17.77%9,776,491$19.55MInsider
David P. Bonita17.77%9,776,491$19.55MInsider
Baker Bros Advisors LP16.82%9,252,951$18.51MInsider
Deerfield Management Company LP Series C7.51%4,133,000$8.27MInstitution
Boxer Capital LLC4.67%2,568,287$5.14MInstitution
Krishna Vaddi2.93%1,611,595$3.22MInsider
Blackrock Inc1.94%1,068,916$2.14MInstitution
Vanguard Group Inc1.84%1,010,565$2.02MInstitution

1 of 3

PRLD vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
PRLD51.83%48.17%Net SellingNet Selling
COYA21.47%13.97%
KPTI54.16%30.17%Net SellingNet Selling
GUTS45.48%54.52%Net BuyingNet Buying
CKPT13.03%15.70%Net Selling
View Top Biotech Stocks

Prelude Therapeutics Stock Ownership FAQ

Who owns Prelude Therapeutics?

Prelude Therapeutics (NASDAQ: PRLD) is owned by 61.64% institutional shareholders, 57.28% Prelude Therapeutics insiders, and 0.00% retail investors. Orbimed Advisors LLC is the largest individual Prelude Therapeutics shareholder, owning 9.78M shares representing 17.77% of the company. Orbimed Advisors LLC's Prelude Therapeutics shares are currently valued at $19.36M.

If you're new to stock investing, here's how to buy Prelude Therapeutics stock.
©2024 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.